We refer to the announcements made on 26 January 2021, 25 February 2021, 11 March 2021, 1 April 2021, 9 April 2021, 30 April 2021, 1 June 2021, 1 September 2021 and 24 November 2021 in relation to the supply agreement dated 12 May 2021 made between a subsidiary of the RDIF (the “Seller”) and DMSB (the “Seller Supply Agreement”) (“Announcements”). For consistency purposes, the abbreviations used in this announcement are the same as those previously defined in the Announcements unless otherwise defined herein.

As highlighted in the announcement made on 24 November 2021, the remaining condition precedent under the Seller Supply Agreement (namely the requirement that the Vaccine be approved by the DCA through technical evaluation by the NPRA) has not been fulfilled on or before the Cut-Off date that expired on 23 November 2021. As such, under the terms and conditions of the Seller Supply Agreement, either party thereto may terminate the said agreement by notice in writing to the other party.

The Board of Directors of Duopharma Biotech Berhad (“Duopharma Biotech”) wishes to announce that DMSB has by letter dated 24 March 2023 terminated the Seller Supply Agreement with effect from the date of the said letter.

The Seller Supply Agreement is in the ordinary course of business of the Duopharma Biotech Group.

This announcement is dated 24 March 2023.